B
SGMO

Bailard’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bailard’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-200,000
Closed -$1.8M – 778
2021
Q3 		$1.8M Sell
200,000
-79,100
-28% -$782K 0.06% 209
2021
Q2 		$3.34M Sell
279,100
-43,500
-13% -$493K 0.12% 155
2021
Q1 		$4.04M Sell
322,600
-69,700
-18% -$939K 0.15% 136
2020
Q4 		$6.12M Buy
392,300
+22,200
+6% +$260K 0.28% 79
2020
Q3 		$3.5M Sell
370,100
-34,900
-9% -$377K 0.18% 106
2020
Q2 		$3.63M Sell
405,000
-46,000
-10% -$427K 0.2% 94
2020
Q1 		$2.87M Buy
451,000
+255,900
+131% +$1.9M 0.2% 99
2019
Q4 		$1.63M Sell
195,100
-55,000
-22% -$506K 0.09% 168
2019
Q3 		$2.26M Buy
250,100
+74,500
+42% +$836K 0.14% 146
2019
Q2 		$1.89M Buy
175,600
+19,500
+12% +$207K 0.12% 163
2019
Q1 		$1.49M Buy
156,100
+123,100
+373% +$1.26M 0.09% 190
2018
Q4 		$379K Sell
33,000
-121,500
-79% -$1.51M 0.03% 367
2018
Q3 		$2.62M Buy
154,500
+77,000
+99% +$1.17M 0.15% 137
2018
Q2 		$1.1M Buy
77,500
+57,500
+288% +$955K 0.07% 210
2018
Q1 		$380K Buy
+20,000
New +$428K 0.02% 382

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bailard's SGMO Position: Q4 2021 in Review

Bailard sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2021, closing a stake of 200,000 shares — an estimated $1.8M sold.

Bailard first reported a position in SGMO in Q1 2018 and held it in 15 quarters. The position peaked at $6.12M in Q4 2020. 193 funds tracked by Wall St. Rank hold SGMO as of Q4 2021.

  • Bailard reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2021 after selling out during the quarter.
  • Bailard sold 200,000 SANGAMO THERAPEUTICS INC shares in Q4 2021, an estimated $1.8M.
  • Bailard first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 15 quarters.
  • Bailard's SANGAMO THERAPEUTICS INC position peaked at $6.12M in Q4 2020.
  • 193 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2021.

Based on Bailard's 13F filing for Q4 2021, filed 10 Feb 2022.